

Amendments to the Claims:

1-66. (Cancelled)

67. (Previously Presented) A pharmaceutical composition comprising:

- (a) an $\alpha_2\delta$ subunit calcium channel modulator selected from the group consisting of Gabapentin and Pregabalin; and
- (b) an antimuscarinic selected from the group consisting of Oxybutynin, Tolterodine, Propiverine, and Solifenacin monohydrochloride;

and wherein said $\alpha_2\delta$ subunit calcium channel modulator and said antimuscarinic are in therapeutically effective amounts sufficient to treat a symptom of a lower urinary tract disorder.

68. (Currently Amended) The pharmaceutical composition of claim 67 wherein said $\alpha_2\delta$ subunit calcium channel modulator is present in an amount from about 50 mg to about 2400 mg, and wherein said antimuscarinic is present in an amount ~~equal to or less than~~ from about .5 mg to about 5 mg.

69. (Previously Presented) The pharmaceutical composition of claim 67 wherein said $\alpha_2\delta$ subunit calcium channel modulator is in an amount of about 200 mg.

70. (Previously Presented) The pharmaceutical composition of claim 67 wherein said antimuscarinic is in an amount of about 2.5 mg.

71. (Previously Presented) The pharmaceutical composition of claim 67 wherein said antimuscarinic is in an amount of about 1.25 mg.

72. (Previously Presented) The pharmaceutical composition of claim 67 wherein said $\alpha_2\delta$ subunit calcium channel modulator and said antimuscarinic are present in a ratio from about 1:1 to about 800:1 or from about 1:1 to about 1:800, respectively.

73. (Previously Presented) The pharmaceutical composition of claim 67 wherein said $\alpha_2\delta$ subunit calcium channel modulator and said antimuscarinic are in a weight/weight ratio of from 1:1 to about 800:1 or from about 1:1 to about 1:800, respectively.

74. (Previously Presented) The pharmaceutical composition of claim 67, wherein said $\alpha_2\delta$ subunit calcium channel modulator and said antimuscarinic are formulated for oral, transmucosal, sublingual, buccal, intranasal, transurethral, rectal, inhalation, topical, transdermal, parenteral, intrathecal, vaginal, or perivaginal administration.

75-79. (Cancelled)

80. (Previously Presented) The pharmaceutical composition of claim 67, wherein said $\alpha_2\delta$ subunit calcium channel modulator is Gabapentin and wherein said antimuscarinic is Oxybutynin.

81. (Previously Presented) The pharmaceutical composition of claim 67, wherein said $\alpha_2\delta$ subunit calcium channel modulator is Gabapentin and wherein said antimuscarinic is Tolterodine.

82. (Previously Presented) The pharmaceutical composition of claim 67, wherein said $\alpha_2\delta$ subunit calcium channel modulator is Gabapentin and wherein said antimuscarinic is Propiverine.

83. (Previously Presented) The pharmaceutical composition of claim 67, wherein said $\alpha_2\delta$ subunit calcium channel modulator is Gabapentin and wherein said antimuscarinic is Solifenacin monohydrochloride.

84. (Previously Presented) The pharmaceutical composition of claim 67, wherein said $\alpha_2\delta$ subunit calcium channel modulator is Pregabalin and wherein said antimuscarinic is

Oxybutynin.

85. (Previously Presented) The pharmaceutical composition of claim 67, wherein said $\alpha_2\delta$ subunit calcium channel modulator is Pregabalin and wherein said antimuscarinic is Tolterodine.

86. (Previously Presented) The pharmaceutical composition of claim 67, wherein said $\alpha_2\delta$ subunit calcium channel modulator is Pregabalin and wherein said antimuscarinic is Propiverine.

87. (Previously Presented) The pharmaceutical composition of claim 67, wherein said $\alpha_2\delta$ subunit calcium channel modulator is Pregabalin and wherein said antimuscarinic is Solifenacin monohydrochloride.

88. (Currently Amended) A pharmaceutical composition comprising Oxybutynin, wherein said Oxybutynin is in an amount ~~less than~~ from about .5 mg to about 2.5 mg.

89-95. (Cancelled)